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Summary 
 
 Blood transfusion and iron chelation currently represents a supportive therapy 
to manage anaemia, vasculopathy and vaso-occlusion crises in Sickle-Cell-Disease.  
 Here we describe the first 5-years long-term randomized clinical trial 
comparing Deferiprone versus Deferoxamine in patients with Sickle-Cell-Disease. 
The results of this study show that Deferiprone has the same effectiveness as 
Deferoxamine in decreasing body iron burden, measured as repeated measurement of 
serum ferritin concentrations on the same patient over 5-years and analyzed 
according to the linear mixed-effects model (LMM) (p=0.822).  
 Both chelators are able to decrease, significantly, serum ferritin concentrations, 
during 5-years, without any effect on safety (p=0.005). Moreover, although the basal 
serum ferritin levels were higher in transfused compared with non transfused group 
(p=0.031), the changes over time in serum ferritin levels was not statistically 
significant different between transfused and non-transfused cohort of patients 
(p=0.389). 
 Kaplan-Meier curve, during 5-years study, suggests that Deferiprone does not 
alter survival in comparison with Deferoxamine (p=0.38).  
 In conclusion, long-term iron chelation therapy with Deferiprone was 
associated with efficacy and safety similar to that of Deferoxamine. Therefore, in 
patients with Sickle-Cell-Disease, Deferiprone may represent an effective long-term 
treatment option. 
 
 
Key points: Chelation in Sickle-Cell-Disease, Effectivenes of Deferiprone in Sickle-
Cell-Disease, DFP versus DFO in Sickle-Cell-Disease 
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Introduction 
 
 Blood transfusion currently represents a supportive therapy to manage 
anaemia, vasculopathy and sickle vaso-occlusion. In adults, aggressive transfusion to 
treat and improve organ dysfunction is used [1,2] more frequently and chronic 
transfusion therapy significantly reduces the risk of primary and secondary stroke in 
paediatric patients with Sickle- Cell-Disease (SCD) [3,4].Therefore, transfusional 
iron overload has been associated with morbidity and mortality in SCD [5].  
 Patients with SCD show differences in iron metabolism and trafficking 
compared with other haemoglobinopathies. Particularly, the effects of inflammatory 
cytokines in SCD may lead to increased iron levels in reticuloendothelial, 
macrophage and renal cells, resulting in different tissues and organs being affected by 
iron overload in SCD compared with β thalassaemia [6]. Moreover, urinary loss of 
iron from intravascular haemolysis and lower levels of Non-Transferrin-Bound-Iron 
(NTBI) due to inflammation may contribute to the different patterns of iron overload 
[7]. 
  Regularly transfused patients with SCD still have increased liver iron 
concentration (LIC), which has been shown to correlate significantly with the volume 
and duration of transfusions. Increased LIC is also associated with liver fibrosis [8-
10].  
 As a result, guidelines currently recommend initiating iron chelation therapy in 
patients with SCD once LIC increases to > 7 mg Fe/g dry weight, if steady state 
serum ferritin levels are >1000 ng/l, or if patients have received cumulative 
transfusions of 120 cc packed red blood cells/kg [1] or at least 20 units of blood 
transfusions [11].  Safety and effectiveness of iron chelation in SCD has been 
reported only in a large prospective clinical trial of Deferasirox (DFX) where patients 
with SCD completing a 1-year, Phase II, randomized, Deferoxamine (DFO)-
controlled study [12] entered a 4-year extension, continuing to receive DFX, or 
switching from DFO to DFX [13].  
 However, long-term safety and effectiveness findings in SCD have not been 
reported from randomized clinical trials comparing oral chelation with DFO. 
Moreover, no data on long-term Deferiprone (DFP) safety and efficacy of DFP 
treatment in SCD has been reported.  
 Therefore, we conducted a 5-year-trial of DFP versus DFO in Italian 
population with SCD to assess the impact of these two chelators on serum ferritin 
concentrations, safety, costs and survival analysis in patients with SCD. 
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Materials and methods 
 
Design 
 
 The trial was a 5-year multicenter randomized open-label trial with blinded 
data management and data analyses, to assess whether either treatment was superior 
to the other.  
 The trial was performed on behalf of the Italian Society for the Study of 
Thalassaemia and Haemoglobinopathies (SoSTE) (http://www.soste.org).  
 The investigators initiated, carried out, and controlled the trial, which was 
conducted without the influence of the sponsor [14]. Other 5-years of follow-up after 
the end of the trial was planned. The trial was registered at 
http://www.clinicaltrials.gov, Identifier NCT00733811. 
 
Patients 
 
 Consecutive SCD patients observed at 9 centers in Italy between January 2001 
and May 2011 were eligible for the trial if they had a serum ferritin concentration 
between 800 and 3000 ng/ml and were over 13 years of age.  
 Parents gave informed consent for patients between 13 and 18 years of age. 
The data were collected at the coordinating centre (A.O.V. Cervello, U.O.C. di 
Ematologia II, Palermo, Italy).  
 The diagnosis of SCD was based on accepted clinical and molecular criteria 
[15]. The exclusion criteria were (i) known intolerance to one of the trial treatments, 
(ii) platelet count <100,000/µl or leucocyte count <3000/µl (iii) severe liver damage 
as indicated by Child-Plugh C grade classification, (iv) sepsis at entry and (v) overt 
heart failure. Eligibility and exclusion criteria were checked at each participating 
centre, where the patients were also seen throughout the entire follow-up period. 
  If the patients were treated with subcutaneous (sc) administration of DFO (30- 
50 mg/kg per day, 8–12 h for 5 d a week) before inclusion in the trial, wash-out from 
DFO for 1 week was performed before randomization after verifying inclusion and 
exclusion criteria. The same timing was used if the patient was on DFX and 
randomized to DFO. Figure 1 shows the trial profile. 
 
 
Randomization 
 
 The randomization sequence was based on a computer randomized list in 
permuted blocks of 10 with a 1:1 ratio, generated at the Department of Scienze 
Economiche, Aziendali e Statistiche of the University of Palermo, Italy. To ensure 
allocation concealment, treatment was assigned by telephone contact from the 
coordinating center. The sequence was concealed until interventions were assigned. 
 Randomization was performed for each consecutive patient after verification of 
the exclusion criteria. Treatment was started within the following 24 h. Patients 
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visited the clinic monthly where clinical and predefined data forms were collected. 
The data were regularly forwarded to the coordinating center, where a complete 
database for all included patients was established.  
 
Interventions 
 
 Trial interventions were DFP (Apotex; Toronto, ON, Canada) at 75 mg/kg/day, 
divided into three oral daily doses, for 7 d/week versus DFO (BiofuturaPharma, 
Pomezia, Italy) by sc infusion (8–10 h) at 50 mg/kg per day for 5 d/week A double-
blinded design was not considered to be possible because of the sc administration of 
DFO. The planned duration of treatment was 5 years.  
 During this period, treatment was only interrupted at the discretion of the 
investigators if needed for intercurrent illness or adverse events (AEs). Count blood 
cell was performed weekly for monitoring, according to the manufacturing 
recommendations for DFP.  
 Dose modifications were allowed for safety reasons. Criteria for dosage 
reduction treatment to DFP 50 mg/kg per day were arthralgia and nausea not 
controlled by symptomatic therapy and for reduction treatment to DFO 30 mg/kg per 
day were local reactions at the site of infusion. Both treatments were reduced if the 
ferritin levels on two consecutive determinations were less than 400 ng/ml. Treatment 
was restarted when ferritin levels were greater than 700 ng/ml on at least two 
determinations.  
 Treatment failure was defined as an increase of serum ferritin levels more than 
1000ng /ml from baseline, confirmed in at least two consecutive determinations. 
Patients who failed were switched to the alternative treatment and followed until the 
end of the study.  
 All outcome assessments were coded by physicians blinded to the trial 
treatment. Drug administration was recorded on the case report form. Assessments 
for safety and efficacy were performed at monthly planned follow-up visits. 
 Compliance was assessed by counting the pills in each returned bag of DFP 
and by assessing the number of infusions of DFO registered on the electronic pump 
(CronoTM, Gene S.r.l., Italy). 
 
Primary and secondary outcomes 
 
 The primary end point of treatment efficacy was the change from the baseline 
value in serum ferritin levels during the 5 years. Secondary endpoints were safety and 
survival analysis at 5-years. 
 
 
 
Follow-up after the trial 
 
 Other 5-years of follow-up, after the end of the trial , was planned to collect 
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data on survival about this cohort of patients. During this period patients were 
allowed to change chelation. Data about causes and chelation treatment at death were 
collected during this period. 
 
Sample size estimation 
 
 Sample size estimation for the two treated groups was performed taking into 
account repeated measures as discussed in Rochon [16]. For our study, the 
recommended number of subjects was between 40 and 100.  
 A minimum number of patients required in each treatment group was 
calculated assuming equal allocation, under the hypothesis of equality between the 
two treatment groups at every point during the course of the trial for the 
autoregressive correlation structure, for a two-sided test at α=0.05, β=0.80, ∆=0.41 
(standardized effect), ρ=0.60, and number of follow-up measurements T = 5. 
 
Costs 
 
 The costs of chelation treatments were calculated for the overall period of 
observation based on cost for 1-day treatment per each person multiplied by the 
person-years of treatment.  
 Periods of reduced dosage were also considered for the cost analysis. The cost 
data were obtained by the Italian Ministry of Health. 
 
Ethics 
 
 The study was conducted according to the Declaration of Helsinki 
(http://www.wma.net/e/policy/b3.html) and was approved by the local Institutional 
Review Board (IRB) of each participant center.  
 The patients (or the parents of minors) gave their written informed consent to 
participate in the trial. Trial was conducted according to GMP and the EU clinical 
trials directive. 
 
Statistical methods 
 
 All descriptive and inferential statistical analyses were performed under code 
of the Department of Scienze Economiche, Aziendali e Statistiche from the 
University of Palermo, by a statistician (A. V.) blinded to the trial interventions, 
using STATA 12.0 software (StataCorp, College Station, TX, USA).  
 Statistical significance is declared when the p-value is less than 0.05. All 
statistical tests are two-sided. For the purpose of statistical analyses, missing scores 
were not included. Thus, observed case analyses have been employed for efficacy 
determinations.  
 Baseline descriptive statistics were presented for each variable. Specifically, 
for categorical variables, the number and the percent of each category within a 
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parameter were calculated for non-missing data, and difference in the two treatment 
arms was compared using a Fisher’s exact test. For continuous variables, the mean, 
standard deviation values were derived, and the comparisons between the baseline 
mean difference in the two intervention groups were based on a t-test.  
 Data on serum ferritin levels consists of repeated measurement on the same 
patient over time. For the purpose of the study a linear mixed-effects model (LMM) 
was used [17]. A mixed model analysis in such a study does not require complete 
data from all subjects. This results in more appropriate estimates of the effect of 
treatment and their standard errors. The analysis was based on a LMM where the 
patient effect (given by the intercept terms for each patient) was regarded as random 
effect, while the treatment effect (treat), the time effect (time), the treatment-by-time 
interaction effect (treat×time), and the total transfutions in ml (tot TX) were regarded 
as fixed effects. In developing this model, the fact that measurements taken on the 
same patient may not be independent of one another, was taken into account. In this 
context, an autoregressive correlation of order 1, AR (1) structure, was considered to 
model correlation within repeated observations. The same analysis (LMM) was 
applied to look at possible statistical significant difference between transfused and 
non-transfused SCD group. 
 The Kaplan–Meier method was used to estimate survival probability for the 
two treated groups of the randomized patients. The survival curves were compared 
per treatment group using the log-rank test. Survival analysis was performed from 
January 30, 2001 to January 30, 2006. Data about causes and chelation at death, after 
5-years from the end of the study was collected and reported. 
 
Results 
 
Participant recruitment and flow 
 
 Consecutive SCD patients (n = 94) between January 30,2001 and January 30, 
2006 were considered to be eligible for the trial (Fig 1).  
 Four patients did not meet inclusion criteria and 30 patients declined to 
participate (Fig 1). The remaining 60 patients were included; 30 and 30 respectively, 
were randomly allocated to DFP versus DFO treatment (Fig 1). No patients were lost 
to follow-up. 
 
Baseline data 
 
 Hematological and clinical findings at enrolment are shown in Table 1. No 
differences were observed at baseline between the two randomized groups (Table 1). 
 Particularly, the degree of iron overload, expressed by serum ferritin at 
baseline, and the amount of blood transfusions requirement, were similar in the two 
groups (Table 1). Therefore, these findings suggest that severity of body iron burden 
was similar between the two groups (Table 1). 
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Serum ferritin concentrations 
 
 Table 2 shows baseline and follow-up mean serum ferritin values during the 5-
year treatment.  
 Table 3 shows results of statistical modelling process to evaluate efficacy of 
DFP versus DFO treatment based on repeated measures of serum ferritin values 
during the study period.  
 Figure 2 shows the fitted effects of serum ferritin levels in the two treatment 
groups. Cases of patients with serum ferritin levels < 400 ng/ml were detected. The 
incidence of patients with serum ferritin levels < 400 ng/ml was higher in the DFP 
group (11 patients, 36.6%) in comparison with the DFO group (1 patient, 3.3%). This 
difference was statistically significant (p-value=0.002).  
 Transfused and non-transfused patients with SCD showed significant changing 
over time in serum ferritin levels (p=0.029) (Table 4). Moreover, although the basal 
serum ferritin levels were higher in transfused compared with non transfused group 
(p=0.031), the changes over time in serum ferritin levels was not statistically 
significant different between the two cohorts of patients (p=0.389) (Table 4).  
 
 
Adverse events and treatment failure 
 
 Table 5 reports the main side effects in the two groups. The overall period of 
observation was 192 person-years for DFP patients compared with 196 person- years 
for DFO patients.  
 Sixteen subjects in the DFP and 13 in the DFO group withdrew definitely from 
the trial (Table 5). The mean time for definitive withdrawal was 77.7±93.8 (days) in 
the DFP group versus 191.4±153 (days) in the DFO group respectively. There was no 
statistically significant difference in temporary and definitive discontinuation of 
treatment between the groups (p=0.764) during the overall period of observation. 
 Dosage decrease was necessary in 2 of DFP patients versus 1 of DFO patients. 
There was only one case of treatment failure in the DFO group and no case in DFP 
group.   
 No patients with agranulocytosis were reported in the DFP-treated group 
(Table 5). Nine and seven patients received hydroxycarbamide during DFP and DFO 
chelation treatment, respectively. 
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 Survival analysis during the trial  
 
 Survival analysis was extended for the 5-years of the trial (Fig. 3). The Kaplan-
Meier survival probability curves of the two treatment groups are reported on Fig. 3. 
The intention-to treat analysis did not show any statistically significant difference 
between the two groups (Fig. 3; p=0.38). The causes of death for single chelation 
treatment are reported on Table 6.  
 
 
Follow-up after the trial  
 
 Data about causes and chelation treatment at death, after 5-years from the end 
of the study, are reported on Table 7. Kaplan-Meier survival probability at 10-years 
(graph not shown) did not show any statistically significant difference between the 
two groups (p=0.88). 
 
 
Compliance and costs 
 
 In the DFP group, compliance was 89%, while with DFO was 75%. The 
calculated mean ± SD cost was 4581 ± 1598 Euros per person-year (range 983 – 
6209) for DFP treatment versus 4966 ± 2117 Euro per person-year (range 488 – 
7352) for DFO treatment. This difference was not statistically significant (p= 0.43). 
 
 
Discussion 
 
 The increased life expectancy of patients with SCD has led to a need for long-
term iron chelation therapy to prevent the onset of complications associated with iron 
overload, but long-term iron chelation data in SCD are currently limited to DFX.  
 The current study is the only study to date to assess the long-term efficacy and 
safety of DFP, during a long-term randomized clinical trial in patients with SCD. The 
results of this study show that DFP has the same effectiveness as DFO in decreasing 
serum ferritin concentration, without increasing adverse events or costs.  
 In a prospective clinical trial of 15 patients with SCD, Voskaridou et al. [18] 
concluded that DFP decreased the serum ferritin levels significantly in 10/12 (83.3%) 
subjects who completed the study. Treatment with deferiprone was not associated 
with any major side effects in this study. Particularly, there was no evidence of 
change in the liver function and no cytopenias, and only one patient had severe 
gastrointestinal side effects.  
 Collins et al., 1994 [19] suggested as the mean daily urinary iron excretion 
induced by DFP at 75mg/kg/d (0.48 ±0.23mg/kg) was equivalent to that induced by 
DFO at 50 mg/kg/d (0.39±0.06 mg/kg).  
 Our findings from a long-term, multicenter, randomized clinical trial 
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demonstrate that DFP was not inferior to DFO in the treatment of iron overload in 
patients with SCD.   
 Serum ferritin levels showed a linear decrease over time in both treatment 
groups but the mean changes of serum ferritin levels over time did not differ between 
the two treated groups. Moreover, applying the linear mixed-effects model (LMM) to 
model serum ferritin in transfused versus non-transfused SCD enrolled patients, there 
was not statistical significant difference in changing over the time of serum ferritin 
levels between these two cohorts of patients (p= 0.389) (Tab. 4), although  the basal 
serum ferritin levels were higher in transfused compared with non-transfused group 
(p=0.031) (Tab. 4). This last finding is similar to that reported by Brown et al., 2009 
[10] who showed relationship between hepatic iron content and the transfusion 
volume in 27 children with sickle cell anemia receiving chronic transfusion therapy 
[10] .  
 The incidence of adverse events was similar between the two treated groups, 
with treatment refusal and local reactions the main adverse events during DFO 
treatment. Although the number of DFP treated patients was limited, the lack of 
agranulocytosis, in DFP treated patients, during an overall period of observation of 
192 person-years may be meaningful. An incidence of agranulocytosis ranging from 
0.4 to 0. 6/100 person-years, as reported for patients with thalassemia major treated 
with DFP [20,21] , might have led to at least one case of agranulocytosis in the 
present trial. Previous trials on DFP in SCD patients did not suggest any effects on 
liver function nor did they report agranulocytosis [18,22,23]. Nine patients enrolled 
on DFP arm also received hydorxycarbamide for prevention of SCD crises. The lack 
of agranulocytosis, during simultaneous treatment with DFP and hydroxycarbamide, 
was previously reported, and the current study increases the number of patients 
treated with DFP and hydroxycarbamide who did not develop agranulocytosis [24]. 
These findings suggest that the risk of agranulocytosis may be acceptable in SCD 
patients treated with DFP.  
 Compliance was better with DFP (89%) in comparison with DFO treatment 
(75%) as suggested by previous clinical trials in thalassemia major patients [25] . 
Moreover, a similar low compliance was observed in several shorter-term SCD 
clinical trials of hydroxyurea [26-28] and during DFX long-term safety and efficacy 
study [13], suggesting that disease and social factors specific to SCD patient 
populations may contribute substantially to low study completion rates [13].  
 The cost analysis did not show a statistical significant difference between the 
two treatment groups (p= 0.43).  
 The results of survival curves, during the trial, even suggest that DFP does not 
alter survival in comparison with DFO (Fig. 3). The causes of death in this study 
were not related to iron overload or chelation therapy but were similar to those found 
in the natural history of SCD [29] (Table 6). These findings are confirmed at the 
follow-up after 5-years from the end of the trial (Tab. 7).  
 The limit of the study could be that serum ferritin levels in patients with SCD 
have shown varying degrees of correlation with LIC, which is considered a more 
direct measure of iron overload, especially in pediatrics patients [30,31].However, the 
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design of the study as randomized clinical trial, the effectiveness of treatment 
evaluated at repeated measurement on the same patient over time of serum ferritin 
levels and the inclusion in the trial of a large cohort of adult patients, may surely have 
balance effect on this bias.  
 In conclusion, long-term iron chelation therapy with DFP was associated with 
efficacy and safety similar to that of DFO. Therefore, in patients with SCD, DFP may 
represent an effective long-term treatment option to accompany on-going transfusion 
therapy, reducing the risk of developing complications of iron overload.  
 These findings, together with those reported for deferasirox[12,13], suggest 
that oral chelation could be now a reasonable choice for the management of iron 
overload in patients with SCD. 
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Appendix 
 
 The following institutions and investigators participated in the Multicenter 
Randomized Clinical Trial of Deferiprone versus Deferoxamine in Sickle Cell 
Disease: Clinical Centers (the numbers in parentheses are the numbers of patients 
enrolled at each center) — Centro per la Talassemia e l’Anemia Falciforme, Azienda 
Sanitaria Provinciale di Caltanissetta Vittorio Emanuele, Gela, Caltanissetta, Italy 
(53): Alessandra Quota and Ketty Perrotta; Unità Operativa Complessa Ematologia II 
, A.O.R. Villa Sofia – V. Cervello, Palermo, Italy (17): Antonino Giangreco and 
Veronica Di Salvo; Centro per la Talassemia, Azienda Ospedaliera Universitaria 
Policlinico Vittorio Emanuele – Santo Bambino, Catania, Italy (9): Turi Lombardo 
and Gaetano Giuffrida; Unità Operativa Complessa di Pediatria, Ospedale Galliera, 
Genova, Italy (6): Gianluca Forni; Unità Operativa Semplice Dipartimentale, 
Azienda Ospedaliera S. Eugenio, Roma, Italy (3): Paolo Cianciulli; Unità Operativa 
Complessa di Medicina Trasfusionale, Azienda Ospedaliera M. Paternò Arezzo, 
Ragusa, Italy (3): Carmelo Fidone; Unità Operativa Semplice di Talassemia, Presidio 
Ospedaliero S. Agata di Militello, Italy (2): Gaetano Roccamo; Unità Operativa 
Complessa di Pediatria, Azienda Ospedaliera S. Antonio Abbate, Trapani, Italy (1): 
Antonella Carollo 
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Table 1. Baseline comparisons in the 60 patients included in the multi-center 
randomized clinical trial comparing Deferiprone (DFP) versus Deferoxamine 
(DFO) in Sickle-Cell-Disease. 
 
Findings  DFP DFO p-value 
N° pts 30 30 --- 
Females (%) 46.67 53.33 0.7970 
Age , years 36.433±13,92 35.83±11.56 0.8565 
Age at first transfusion, years 6.95±8.03 7.81±11.94 0.7605 
Mean age at DFO starting , years 29.09±14.75 29.77±12.03 0.8593 
Hgb, gr/dl* 9.59±1.68 9.26±1.27 0.4042 
ALT, IU/L*  37.51±22.24 45.97±41.67 0.3395 
Total blood 
transfusion,(ml/year) 2055.05±1282.01 2797.15 ±2018.08 0.1901 
Mean Hb pre-Tx, gr/dl 8.99±1.32 8.65±0.99 0.2955 
Mean basal ferritin, ng/ml  1440.14±712.7 1726.03±694.01 0.1274 
Mean basal EF   (%) 59.91±6.65 60.83±8.52 0.7731 
Splenectomy  (%) 45.4 70.6 0.1910 
Cirrhosis  (%) 13.3 11.5 1.000 
Arrhythmia  (%) 10.0 15.4 0.693 
HCV-RNA positive  (%) 18.52 12.00 0.705 
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Table 2. Means of serum ferritin levels (μg/l) during 5-year multi-center 
randomized clinical trial comparing Deferiprone (DFP) versus Deferoxamine 
(DFO) treatment in Sickle-Cell-Disease. 
DFP DFO 
Years mean±sd (n) mean±sd (n) 
Baseline  1440.13±712.80 (29) 1726.03±694.01 (29) 
1 1033.00±737.41 (19) 1522.64±954.98 (22) 
2 1076.80±897.51 (15) 1100.05±798.61 (19) 
3 580.10±581.56 (10) 1127.68±516.42 (16) 
4  438.22±320.81 (9) 1078.26±356.31 (15) 
5 695.00±597.74 (7) 1333.85±871.74 (14) 
 
 
 
 
 
Table 3.  Linear Mixed Effect Model (LMM) to evaluate changes over time in 
mean serum ferritin levels in Deferiprone versus Deferoxamine-treated group in 
Sickle-Cell-Disease. 
 
  
Coefficients  SE  95% CI*  p-
value  
Intercept  1433.02 206.54  (1028.21; 1837.84)  0.000  
treat  -53.03  235.21  (-514.02; 407.95)  0.822  
time  -184.85  66.52  (-315.23; -54.48)  0.005  
treatXtime  112.61  81.69  (-47.52; 272.72)  0.168 
totTX  0.11  0.05  (-0.01; 0.21)  0.055 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 18
 
Table 4.  Linear Mixed Effect Model (LMM) to evaluate changes over time in 
mean serum ferritin levels of transfused versus non-transfused patients with 
Sickle-Cell-Disease enrolled in the multi-center randomized trial.  
 
     
  Coefficients  SE 95% CI* p-value 
Intercept 1149,13 200,88 (755.42; 1542.86) 0.000 
TX 495,96 229,71 (45.75; 946.17) 0,031 
time -179,81 82,54 (-341.57; -18.03) 0,029 
TXxtime 78,11 90,61 (-99.48; 255.70) 0,389 
     
 
 
 
 
Table 5. Adverse events (AEs) in Sickle-Cell-Disease during the 5 years trial 
comparing Deferiprone versus Deferoxamine. 
 
DFP        DFO   
Adverse events N % n % p-value 
Local reactions at the 
infusion site 
--- --- 3 10.0 0.237 
Fever or other 
infections 
3 10.0 --- --- 0.237 
Joint pain 2 6.7  ---  --- 0.492 
Nausea 4   13.3  ---  ---  0.112 
Vomit 2 6.7  ---  ---  0.492 
Liver damage*  3 10  ---  --- 0.237 
Treatment refusal 1 3.3 16 53.3 <0.001 
SCD crisis 2 6.7 1 3.3 1.000 
Surgery   ---  --- 2 6.7  0.492 
Mastitis 2 6.7  ---  ---  0.492 
            
*increase  twice the normal value. 
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Table 6. Causes of death, at 5-years, in patients included in the Sickle-Cell-
Disease multi-center randomized clinical trial comparing Deferiprone versus 
Deferoxamine. 
 
Causes of death n (%) *Treatment 
Acute Chest Syndrome 1 (16.7) DFP 
Respiratory failure 2(33.3)  DFO 
Hepatic failure  3(50.0)       2DFO1DFP 
Totals 6   
*Treatment at randomization 
 
 
 
 
Table 7. Causes of death, at 10-years, in patients included in the Sickle-Cell-
Disease multi-center randomized clinical trial. 
 
Causes of death n (%) *Treatment 
Acute Chest Syndrome 1 (7,1) DFO 
Respiratory failure   4 (28,6) 
 
3 DFO, 1 DFP 
Hepatic failure    5 (35,9) DFO 
Marasmus senile 1 (7,1) DFO 
Averse events post vaccination in liver transplant 1 (7,1) DFO 
Cardio-circulatory arrest in pulmonary hypertension 1 (7,1) DFO 
Pulmonary embolism 1 (7,1) DFO 
Totals 14   
*Treatment at death. 
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Figure 1. Trial profile of Deferiprone versus Deferoxamine intervention during 
the Sickle-Cell-Disease multi-center randomized clinical trial. 
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Figure 2. Estimated profiles of the mean serum ferritin  in the two treatment-
groups from the fitted Linear Mixed-Effects Model (LMM) during Sickle-Cell-
Disease multi-center randomized clinical trial. 
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Figure 3. Kaplan–Meier survival probability curves in the two treatment groups 
during multi-center Sickle-Cell-Disease clinical trial  (Deferiprone: continous 
line; Deferoxamine: dashed line) (p=0.38) 
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